- The Shift
- Posts
- Anthropic’s Biggest Claude Moves Yet
Anthropic’s Biggest Claude Moves Yet
🤩 KAIST’s researchers revolutionize cancer drug design, Create cinematic product videos in minutes with Seedance Pro, and more!
Hello there! Ready to dive into another upgrading, Mind-boggling, and Value-filled Shift?
Today we have:
🚀 Anthropic Expands Claude’s Capabilities with 1M Context, $1 Gov Access, and Chat Memory
🤩Create Pro-Grade Product Videos with Seedance Pro in Higgsfield
🧪 KAIST’s BInD: AI That Designs Cancer Drugs from Scratch
🔨Tools and Shifts you cannot miss
🚀 Anthropic Expands Claude’s Capabilities with 1M Context, $1 Gov Access, and Chat Memory
Anthropic just rolled out its biggest upgrades yet for Claude, from record-breaking context windows to government expansion and smarter chat continuity. The move positions Claude to compete harder with GPT-5, win developer loyalty, and deepen its public sector footprint.
The Shift:
1. 1M Token Context for Claude Sonnet 4 - Enterprise/API users can now feed Claude Sonnet 4 up to 1M tokens, that’s 750,000 words or 75,000 lines of code, over 5× its previous limit. Available via API, AWS Bedrock, and Google Vertex AI, with tiered pricing for prompts over 200k tokens.
2. Strategic Public Sector Play - In a direct challenge to OpenAI, Anthropic is offering Claude to all three branches of the U.S. government for $1/year for one year. The package includes Claude for Government with FedRAMP High certification, supporting sensitive unclassified workloads and multi-cloud deployment via AWS, Google Cloud, and Palantir.
3. Chat Continuity for Enterprise Plans - A new memory feature lets Claude recall and reference past conversations, making it easier to resume projects without re-prompting. Rolling out now to Max, Team, and Enterprise tiers, with broader availability on the way.
Anthropic is stacking capability, price strategy, and platform usability to lock in enterprise and government clients while fending off GPT-5. For developers, coders, and public sector teams, these updates mean more context, more control, and less friction in using AI at scale.
🤩Create Pro-Grade Product Videos with Seedance Pro in Higgsfield
Open Create → Video – Sign in at higgsfield.ai and select Seedance Pro as your model.
Choose Motion – Pick a camera move (push-in, orbit, dolly, etc.) that fits your product story.
Upload Image – Add a clean product shot (PNG/JPG).
Write Prompt & Generate – Describe scene, lighting, background, and vibe. Click Generate, tweak motion or prompt if needed.
Add More Shots – Repeat with new angles and motions for variety.
Assemble & Export – Combine clips in Canvas, add text/logo, export in desired format.
Conclusion: With Seedance Pro, you can go from static image to multi-shot cinematic product video in minutes, perfect for ads, launches, or social content without a film crew.
🧪 KAIST’s BInD: AI That Designs Cancer Drugs from Scratch
KAIST researchers have unveiled BInD, an AI model that can design optimal cancer drug candidates from only the target protein’s structure, no prior molecular data required. It combines drug creation and binding mechanism prediction into a single step, streamlining discovery. This breakthrough promises faster, more precise, and more cost-effective pathways for life-saving medicines.
The Shift:
1. One-step design for targeted drugs - BInD generates the drug molecule and predicts how it will bind to diseased proteins simultaneously, eliminating the traditional trial-and-error cycles of designing and testing separately.
2. Precision and safety built in - The AI designs molecules that selectively bind to cancer-causing mutations while sparing healthy protein versions, optimizing for multiple factors, binding affinity, drug-like properties, and stability, at once, avoiding trade-offs common in older systems.
3. Learns and improves with “recycling” - BInD reuses successful binding patterns from prior results, improving new drug candidates without retraining. It’s grounded in chemical laws like bond lengths and protein-ligand distances for realistic structure generation. The model successfully targeted mutated EGFR proteins linked to cancer.
Drug discovery is slow, risky, and expensive, but BInD’s generative, one-step process could slash timelines and open the door to tailored, effective cancer treatments. With AI-designed drugs already emerging, tools like BInD could accelerate a wave of transformative medicines.
🔨AI Tools for the Shift
📱 TheLibrarian.io – Supercharge your day with a WhatsApp AI Assistant. Get instant answers, reminders, and task automation directly in chat.
✍️ Outwrite – Create content AI systems cite 10x more. Designed for writers, researchers, and marketers who need high-authority output.
🛍️ Etshop – Discover best-selling products on Etsy. Perfect for eCommerce sellers seeking trending ideas and competitive insights.
🧪 TestDriver – The first QA AI agent for engineering teams. Runs automated tests, catches bugs early, and speeds up releases.
📚 15Minutes – Get any book's essence in 15 minutes. Save time with concise, actionable summaries you can read or listen to.
🚀Quick Shifts
💼 Perplexity made a $34.5B bid for Google’s Chrome, pledging open-source investment and keeping Google search, amid DOJ antitrust pressure, despite its valuation and funding being far below the offer.
👨💻 The Trump administration says its 15% revenue-sharing deal for AI chip exports to China is still under legal review by the Department of Commerce, and could later extend to other companies.
🤖 OpenAI restored ChatGPT’s model picker with Auto, Fast, and Thinking modes for GPT-5, re-enabled legacy models, and plans personality updates after router issues and user backlash over model deprecations.
🧠 Mistral launched Medium 3.1, an upgraded model with stronger performance and enhanced creative writing, offering improved narrative quality, style versatility, and overall capability for a range of applications.
⚖️ Elon Musk says xAI will sue Apple, alleging its App Store rankings unfairly favor OpenAI’s ChatGPT over his apps, X and Grok. Apple denies bias, citing objective curation criteria. OpenAI CEO Sam Altman countered by pointing to past claims that Musk boosted his own posts on X.
Reply